AngioDynamics, Inc. ANGO recently announced that Irreversible Electroporation (IRE) has received Current Procedural Terminology (CPT) Category I codes for the treatment of lesions in the prostate and ...

Peer-reviewed findings demonstrate high disease control and quality-of-life preservation, supporting shift toward focal therapy in prostate treatment “The publication of the PRESERVE study in European ...

Function-Preserving Therapy Recognized in the Medical Devices Category for its Use of Irreversible Electroporation (IRE) Technology in Treatment of Prostate Tumors For the past 25 years, TIME’s Best ...

LATHAM, N.Y.--(BUSINESS WIRE)-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, ...

TIME names NanoKnife one of 2025’s Best Inventions — already treating prostate cancer in Toronto with precise, function-preserving results. TIME's recognition of NanoKnife (IRE) reinforces what we’ve ...

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, ...

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, ...

Defense Secretary Lloyd Austin's medical issues last December put the spotlight on fighting prostate cancer while reducing the risk of side effects and complications. A trial here on a less invasive ...

AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options ...